RBM11
gene geneOn this page
Summary
RBM11 (RNA binding motif protein 11, HGNC:9897) is a protein-coding gene on chromosome 21q11.2, encoding Splicing regulator RBM11 (P57052). Tissue-specific splicing factor with potential implication in the regulation of alternative splicing during neuron and germ cell differentiation.
Enables poly(U) RNA binding activity and protein homodimerization activity. Acts upstream of or within cellular response to oxidative stress and regulation of alternative mRNA splicing, via spliceosome. Located in nuclear speck.
Source: NCBI Gene 54033 — RefSeq curated summary.
At a glance
- Clinical variants (ClinVar): 51 total
- MANE Select transcript:
NM_144770
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:9897 |
| Approved symbol | RBM11 |
| Name | RNA binding motif protein 11 |
| Location | 21q11.2 |
| Locus type | gene with protein product |
| Status | Approved |
| Ensembl gene | ENSG00000185272 |
| Ensembl biotype | protein_coding |
| OMIM | 617937 |
| Entrez | 54033 |
Gene structure
Transcript identifiers
Ensembl transcripts: 7 — 4 protein_coding_CDS_not_defined, 2 protein_coding, 1 retained_intron
ENST00000400577, ENST00000461088, ENST00000468643, ENST00000468788, ENST00000475864, ENST00000495055, ENST00000900829
RefSeq mRNA: 2 — MANE Select: NM_144770
NM_001320602, NM_144770
CCDS: CCDS46635
Canonical transcript exons
ENST00000400577 — 5 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001939246 | 14216157 | 14216282 |
| ENSE00003485052 | 14224438 | 14224537 |
| ENSE00003529564 | 14226880 | 14228372 |
| ENSE00003546298 | 14219563 | 14219725 |
| ENSE00003560060 | 14221097 | 14221169 |
Expression profiles
Bgee: expression breadth ubiquitous, 194 present calls, max score 97.62.
FANTOM5 (CAGE): breadth broad, TPM avg 4.3325 / max 598.0450, expressed in 728 samples.
FANTOM5 promoters (2 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 188483 | 4.0660 | 720 |
| 188484 | 0.2664 | 77 |
Top tissues by expression
246 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| corpus epididymis | UBERON:0004359 | 97.62 | gold quality |
| C1 segment of cervical spinal cord | UBERON:0006469 | 90.47 | gold quality |
| spinal cord | UBERON:0002240 | 89.37 | gold quality |
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 88.37 | gold quality |
| primordial germ cell in gonad | CL:0000670 ∩ UBERON:0000991 | 88.01 | gold quality |
| oocyte | CL:0000023 | 87.51 | gold quality |
| tibial nerve | UBERON:0001323 | 84.65 | gold quality |
| left ovary | UBERON:0002119 | 80.97 | gold quality |
| Brodmann (1909) area 9 | UBERON:0013540 | 80.81 | gold quality |
| prefrontal cortex | UBERON:0000451 | 80.52 | gold quality |
| secondary oocyte | CL:0000655 | 79.81 | gold quality |
| adenohypophysis | UBERON:0002196 | 79.78 | gold quality |
| cortical plate | UBERON:0005343 | 79.26 | gold quality |
| hypothalamus | UBERON:0001898 | 78.72 | gold quality |
| islet of Langerhans | UBERON:0000006 | 78.54 | gold quality |
| right ovary | UBERON:0002118 | 78.26 | gold quality |
| dorsolateral prefrontal cortex | UBERON:0009834 | 77.89 | gold quality |
| anterior cingulate cortex | UBERON:0009835 | 77.77 | gold quality |
| lower esophagus mucosa | UBERON:0035834 | 77.54 | gold quality |
| left lobe of thyroid gland | UBERON:0001120 | 77.49 | gold quality |
| pituitary gland | UBERON:0000007 | 77.27 | gold quality |
| ovary | UBERON:0000992 | 76.72 | gold quality |
| right frontal lobe | UBERON:0002810 | 76.63 | gold quality |
| frontal cortex | UBERON:0001870 | 76.53 | gold quality |
| thyroid gland | UBERON:0002046 | 76.44 | gold quality |
| neocortex | UBERON:0001950 | 76.38 | gold quality |
| substantia nigra | UBERON:0002038 | 76.27 | gold quality |
| right lobe of thyroid gland | UBERON:0001119 | 76.05 | gold quality |
| cerebral cortex | UBERON:0000956 | 74.92 | gold quality |
| caput epididymis | UBERON:0004358 | 74.30 | gold quality |
Single-cell (SCXA)
Detected in 1 experiment(s), a significant marker in 0.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | no | 2.81 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
69 targeting RBM11, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-3163 | 100.00 | 77.23 | 8605 |
| HSA-MIR-5692A | 100.00 | 74.40 | 6850 |
| HSA-MIR-5011-5P | 100.00 | 83.46 | 5820 |
| HSA-MIR-190A-3P | 100.00 | 80.35 | 5520 |
| HSA-MIR-1277-5P | 100.00 | 73.95 | 5056 |
| HSA-MIR-3662 | 99.99 | 73.82 | 5684 |
| HSA-MIR-3185 | 99.99 | 68.12 | 1959 |
| HSA-MIR-433-3P | 99.98 | 69.37 | 1203 |
| HSA-MIR-568 | 99.98 | 69.86 | 2084 |
| HSA-MIR-548P | 99.98 | 72.25 | 3784 |
| HSA-MIR-485-3P | 99.98 | 70.68 | 1585 |
| HSA-MIR-539-3P | 99.98 | 70.74 | 1616 |
| HSA-MIR-1250-3P | 99.96 | 70.04 | 4038 |
| HSA-MIR-590-3P | 99.96 | 74.34 | 6478 |
| HSA-MIR-146A-5P | 99.96 | 68.93 | 988 |
| HSA-MIR-146B-5P | 99.96 | 69.13 | 977 |
| HSA-MIR-7153-5P | 99.94 | 68.89 | 1006 |
| HSA-MIR-335-3P | 99.93 | 73.36 | 4958 |
| HSA-MIR-3119 | 99.92 | 71.34 | 2390 |
| HSA-MIR-4496 | 99.88 | 68.89 | 2236 |
| HSA-MIR-4659A-3P | 99.80 | 72.62 | 4248 |
| HSA-MIR-4659B-3P | 99.80 | 72.62 | 4248 |
| HSA-MIR-548AJ-5P | 99.78 | 71.12 | 3085 |
| HSA-MIR-548F-5P | 99.78 | 71.02 | 3093 |
| HSA-MIR-548G-5P | 99.78 | 71.12 | 3085 |
| HSA-MIR-548X-5P | 99.78 | 71.12 | 3085 |
| HSA-MIR-4658 | 99.77 | 64.94 | 514 |
| HSA-MIR-6790-5P | 99.77 | 65.24 | 505 |
| HSA-MIR-3659 | 99.70 | 67.97 | 694 |
| HSA-MIR-29B-2-5P | 99.67 | 68.98 | 1726 |
Literature-anchored findings (GeneRIF, showing 2)
- RBM11 is a representative splicing factor that is upregulated in glioblastoma tumors after therapy and shed in extracellular vesicles upon induction of apoptosis. Once internalized in recipient cells, exogenous RBM11 switches splicing of MDM4 and Cyclin D1 toward the expression of more oncogenic isoforms. (PMID:29937354)
- RNA-Binding Motif Protein 11 (RBM11) Serves as a Prognostic Biomarker and Promotes Ovarian Cancer Progression. (PMID:34434291)
Cross-species orthologs
6 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | rbm11 | ENSDARG00000090202 |
| mus_musculus | Rbm11 | ENSMUSG00000032940 |
| rattus_norvegicus | Rbm11 | ENSRNOG00000029147 |
| drosophila_melanogaster | CG11454 | FBGN0031224 |
| caenorhabditis_elegans | WBGENE00012558 | |
| caenorhabditis_elegans | rnp-8 | WBGENE00020091 |
Paralogs (1): RBM7 (ENSG00000076053)
Protein
Protein identifiers
Splicing regulator RBM11 — P57052 (reviewed: P57052)
Alternative names: RNA-binding motif protein 11
All UniProt accessions (1): P57052
UniProt curated annotations — full annotation on UniProt →
Function. Tissue-specific splicing factor with potential implication in the regulation of alternative splicing during neuron and germ cell differentiation. Antagonizes SRSF1-mediated BCL-X splicing. May affect the choice of alternative 5’ splice sites by binding to specific sequences in exons and antagonizing the SR protein SRSF1.
Subunit / interactions. Homodimer.
Subcellular location. Nucleus. Nucleoplasm. Nucleus speckle.
Tissue specificity. Expressed in brain, hippocampus, prefrontal cortex, cerebellum, spinal cord, testis, mammary gland, spleen and kidney. Also expressed in fetal brain.
Miscellaneous. May be produced at very low levels due to a premature stop CC codon in the mRNA, leading to nonsense-mediated mRNA decay.
Isoforms (2)
| UniProt ID | Names | Canonical? |
|---|---|---|
| P57052-1 | 1 | yes |
| P57052-3 | 3 |
RefSeq proteins (2): NP_001307531, NP_658983* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR000504 | RRM_dom | Domain |
| IPR012677 | Nucleotide-bd_a/b_plait_sf | Homologous_superfamily |
| IPR034501 | RBM11_RRM | Domain |
| IPR035979 | RBD_domain_sf | Homologous_superfamily |
| IPR052285 | NEXT_complex_subunit | Family |
Pfam: PF00076
UniProt features (18 total): helix 4, strand 3, compositionally biased region 3, splice variant 2, chain 1, domain 1, sequence conflict 1, region of interest 1, short sequence motif 1, sequence variant 1
Structure
Experimental structures (PDB)
1 structures.
| PDB | Method | Resolution (Å) |
|---|---|---|
| 2YWK | X-RAY DIFFRACTION | 1.54 |
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-P57052-F1 | 61.85 | 0.28 |
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 90 (showing top):
GOBP_ALTERNATIVE_MRNA_SPLICING_VIA_SPLICEOSOME, GOBP_RNA_SPLICING, GOBP_REGULATION_OF_MRNA_SPLICING_VIA_SPLICEOSOME, GOBP_REGULATION_OF_RNA_SPLICING, GOCC_NUCLEAR_SPECK, GOCC_NUCLEAR_BODY, TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_8D_UP, GOCC_RIBONUCLEOPROTEIN_GRANULE, GOMF_PROTEIN_DIMERIZATION_ACTIVITY, GOMF_PROTEIN_HOMODIMERIZATION_ACTIVITY, GOMF_POLY_PYRIMIDINE_TRACT_BINDING, GOMF_SINGLE_STRANDED_RNA_BINDING, GOBP_REGULATION_OF_MRNA_PROCESSING, GOBP_MRNA_PROCESSING, GOCC_SUPRAMOLECULAR_COMPLEX
GO Biological Process (5): regulation of alternative mRNA splicing, via spliceosome (GO:0000381), mRNA processing (GO:0006397), RNA splicing (GO:0008380), cell differentiation (GO:0030154), cellular response to oxidative stress (GO:0034599)
GO Molecular Function (6): single-stranded RNA binding (GO:0003727), poly(U) RNA binding (GO:0008266), protein homodimerization activity (GO:0042803), nucleic acid binding (GO:0003676), RNA binding (GO:0003723), protein binding (GO:0005515)
GO Cellular Component (3): nucleus (GO:0005634), nucleoplasm (GO:0005654), nuclear speck (GO:0016607)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| RNA processing | 2 |
| binding | 2 |
| alternative mRNA splicing, via spliceosome | 1 |
| regulation of mRNA splicing, via spliceosome | 1 |
| mRNA metabolic process | 1 |
| cellular developmental process | 1 |
| response to oxidative stress | 1 |
| cellular response to chemical stress | 1 |
| RNA binding | 1 |
| poly-pyrimidine tract binding | 1 |
| identical protein binding | 1 |
| protein dimerization activity | 1 |
| nucleic acid binding | 1 |
| intracellular membrane-bounded organelle | 1 |
| nuclear lumen | 1 |
| cellular anatomical structure | 1 |
| nuclear ribonucleoprotein granule | 1 |
Protein interactions and networks
STRING
1049 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| RBM11 | RBM25 | P49756 | 652 |
| RBM11 | RBM4 | Q9BWF3 | 616 |
| RBM11 | KHDRBS1 | Q07666 | 595 |
| RBM11 | RBM10 | P98175 | 594 |
| RBM11 | MDM4 | O15151 | 559 |
| RBM11 | SRSF1 | Q07955 | 527 |
| RBM11 | ZCCHC8 | Q6NZY4 | 517 |
| RBM11 | HSPA13 | P48723 | 490 |
| RBM11 | LIPI | Q6XZB0 | 489 |
| RBM11 | RBM19 | Q9Y4C8 | 487 |
| RBM11 | FBF1 | Q8TES7 | 478 |
| RBM11 | RBM17 | Q96I25 | 476 |
| RBM11 | TRA2B | P62995 | 474 |
| RBM11 | PCBP3 | P57721 | 473 |
| RBM11 | SF3B2 | Q13435 | 454 |
IntAct
178 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| MED4 | MED19 | psi-mi:“MI:2364”(proximity) | 0.900 |
| RBM11 | ZCCHC8 | psi-mi:“MI:0914”(association) | 0.740 |
| QKI | RBM11 | psi-mi:“MI:0915”(physical association) | 0.560 |
| GABPB1 | RBM11 | psi-mi:“MI:0915”(physical association) | 0.560 |
| RBM11 | SNRPC | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZNF774 | RBM11 | psi-mi:“MI:0915”(physical association) | 0.560 |
| RBM11 | QKI | psi-mi:“MI:0915”(physical association) | 0.560 |
| SNRPC | RBM11 | psi-mi:“MI:0915”(physical association) | 0.560 |
| PIBF1 | RBM11 | psi-mi:“MI:0915”(physical association) | 0.560 |
| U2AF2 | RBM11 | psi-mi:“MI:0915”(physical association) | 0.560 |
| RBM11 | ATOSB | psi-mi:“MI:0915”(physical association) | 0.560 |
| RBM11 | GPATCH2L | psi-mi:“MI:0915”(physical association) | 0.560 |
| SNRPA | RBM11 | psi-mi:“MI:0915”(physical association) | 0.560 |
| RBM11 | PIBF1 | psi-mi:“MI:0915”(physical association) | 0.560 |
| RBM11 | SCNM1 | psi-mi:“MI:0915”(physical association) | 0.560 |
| RBM11 | GLIS2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| DDX6 | RBM11 | psi-mi:“MI:0915”(physical association) | 0.560 |
| RBM11 | ZFHX3 | psi-mi:“MI:0915”(physical association) | 0.560 |
| RBM11 | DTX2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| RBM11 | SAXO4 | psi-mi:“MI:0915”(physical association) | 0.560 |
| RBM11 | ZNF414 | psi-mi:“MI:0915”(physical association) | 0.560 |
| RBM11 | GADD45GIP1 | psi-mi:“MI:0915”(physical association) | 0.560 |
| RBM11 | ENKD1 | psi-mi:“MI:0915”(physical association) | 0.560 |
BioGRID (194): RBM11 (Two-hybrid), RBM11 (Two-hybrid), RBM11 (Two-hybrid), ZNF774 (Two-hybrid), SF3B2 (Affinity Capture-MS), SKIV2L2 (Affinity Capture-MS), USP7 (Affinity Capture-MS), SLC4A1AP (Affinity Capture-MS), ZCCHC8 (Affinity Capture-MS), TTC33 (Affinity Capture-MS), RHOXF2 (Two-hybrid), RBM11 (Reconstituted Complex), RBM11 (Proximity Label-MS), DAZAP2 (Two-hybrid), SLC4A1AP (Affinity Capture-MS)
ESM2 similar proteins: A0A087WUL8, A0A0J9YWL9, A0A0J9YY54, A0A1L8G2K9, A6NJ88, A6QL64, B4DH59, B5DUH6, B7SY83, B9G9L9, F4HXQ7, O04492, O77733, P0DKJ7, P0DKJ8, P0DKL2, P0DPF3, P17772, P48785, P48786, P53353, P57052, Q0DVU4, Q15361, Q3BBV0, Q3BBV2, Q4ZJY7, Q4ZJZ0, Q4ZJZ1, Q4ZJZ3, Q5JPF3, Q5TAG4, Q5TI25, Q5XHX6, Q5ZCC5, Q6P3W6, Q6P902, Q6PGQ1, Q6ZQX7, Q86T75
Diamond homologs: A0A0D1DZT6, A3LXL0, B1WC40, B5FXN8, B5G279, F4HT49, O08583, O22173, O35698, O64380, O75821, O93235, P04147, P19683, P19684, P27476, P29341, P42731, P49313, P49314, P52298, P57052, P60824, P60825, P60826, Q06106, Q08935, Q08937, Q09330, Q10355, Q13595, Q14011, Q1ZXC2, Q28CY2, Q28FB9, Q28IQ9, Q29RT0, Q2GSX8, Q3T0I4, Q3ZBJ1
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
51 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 41 |
| Likely benign | 4 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
1094 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 21:14221093:A:AG | acceptor_gain | 1.0000 |
| 21:14221093:AAAG:A | acceptor_gain | 1.0000 |
| 21:14221093:AAAGG:A | acceptor_gain | 1.0000 |
| 21:14221094:A:G | acceptor_gain | 1.0000 |
| 21:14221096:GGGA:G | acceptor_gain | 1.0000 |
| 21:14216253:G:GT | donor_gain | 0.9900 |
| 21:14216278:TTCAG:T | donor_loss | 0.9900 |
| 21:14216280:CAG:C | donor_loss | 0.9900 |
| 21:14216281:AGG:A | donor_loss | 0.9900 |
| 21:14216282:GGTAC:G | donor_loss | 0.9900 |
| 21:14216283:G:A | donor_loss | 0.9900 |
| 21:14216284:T:G | donor_loss | 0.9900 |
| 21:14219712:GC:G | donor_gain | 0.9900 |
| 21:14221091:TCAAA:T | acceptor_loss | 0.9900 |
| 21:14221092:CAAA:C | acceptor_loss | 0.9900 |
| 21:14221094:AAG:A | acceptor_gain | 0.9900 |
| 21:14221095:A:G | acceptor_gain | 0.9900 |
| 21:14221095:AG:A | acceptor_gain | 0.9900 |
| 21:14221095:AGGG:A | acceptor_loss | 0.9900 |
| 21:14221096:G:GG | acceptor_gain | 0.9900 |
| 21:14221096:GG:G | acceptor_gain | 0.9900 |
| 21:14221166:ACAG:A | donor_loss | 0.9900 |
| 21:14221167:CAG:C | donor_loss | 0.9900 |
| 21:14221169:GG:G | donor_loss | 0.9900 |
| 21:14221170:GTAAT:G | donor_loss | 0.9900 |
| 21:14221171:TAATT:T | donor_loss | 0.9900 |
| 21:14216253:G:T | donor_gain | 0.9800 |
| 21:14218103:C:CG | donor_gain | 0.9800 |
| 21:14218103:C:G | donor_gain | 0.9800 |
| 21:14219723:TTGGT:T | donor_loss | 0.9800 |
AlphaMissense
1857 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 21:14216227:T:A | V14D | 1.000 |
| 21:14219624:G:A | G53E | 1.000 |
| 21:14219630:T:A | V55D | 1.000 |
| 21:14219675:T:C | L70P | 1.000 |
| 21:14216223:T:C | F13L | 0.999 |
| 21:14216225:T:A | F13L | 0.999 |
| 21:14216225:T:G | F13L | 0.999 |
| 21:14216236:T:C | L17S | 0.999 |
| 21:14216263:T:A | L26Q | 0.999 |
| 21:14216263:T:C | L26P | 0.999 |
| 21:14216272:T:C | L29P | 0.999 |
| 21:14216274:T:C | F30L | 0.999 |
| 21:14216276:C:A | F30L | 0.999 |
| 21:14216276:C:G | F30L | 0.999 |
| 21:14219566:G:A | G34R | 0.999 |
| 21:14219566:G:C | G34R | 0.999 |
| 21:14219566:G:T | G34W | 0.999 |
| 21:14219567:G:A | G34E | 0.999 |
| 21:14219620:T:C | F52L | 0.999 |
| 21:14219622:T:A | F52L | 0.999 |
| 21:14219622:T:G | F52L | 0.999 |
| 21:14219623:G:A | G53R | 0.999 |
| 21:14219623:G:C | G53R | 0.999 |
| 21:14219626:T:C | F54L | 0.999 |
| 21:14219628:T:A | F54L | 0.999 |
| 21:14219628:T:G | F54L | 0.999 |
| 21:14219635:T:C | F57L | 0.999 |
| 21:14219636:T:C | F57S | 0.999 |
| 21:14219637:T:A | F57L | 0.999 |
| 21:14219637:T:G | F57L | 0.999 |
dbSNP variants (sampled 300 via entrez): RS1000085994 (21:14223859 C>A), RS1000444485 (21:14228005 C>G), RS1000531068 (21:14222234 C>A,T), RS1000583269 (21:14221954 A>G), RS1001160195 (21:14216209 C>G), RS1001291083 (21:14228592 A>G,T), RS1001487211 (21:14223750 G>C), RS1001950015 (21:14227598 T>C), RS1002358880 (21:14227862 A>G), RS1002482192 (21:14215499 C>T), RS1002486732 (21:14222575 C>T), RS1002540903 (21:14222396 T>C), RS1002967726 (21:14226121 C>T), RS1002975359 (21:14216365 G>A,C,T), RS1003088434 (21:14220402 C>T)
Disease associations
OMIM: gene MIM:617937 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
0 associations (top):
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
11 total (human), top 11 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| Valproic Acid | increases expression | 3 |
| trichostatin A | affects expression, increases expression | 2 |
| p-Chloromercuribenzoic Acid | affects cotreatment, increases expression | 2 |
| potassium chromate(VI) | increases expression | 1 |
| entinostat | increases expression | 1 |
| 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | increases expression, affects cotreatment | 1 |
| dorsomorphin | affects cotreatment, increases expression | 1 |
| Vorinostat | increases expression | 1 |
| Benzo(a)pyrene | increases methylation | 1 |
| Cadmium Chloride | decreases expression | 1 |
| S-Nitrosoglutathione | increases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.